Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale... see more

Recent & Breaking News (NDAQ:GRFS)

Grifols HyperRAB® (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection

PR Newswire February 6, 2018

Grifols Misterium® Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation

PR Newswire December 4, 2017

Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma

PR Newswire November 27, 2017

Breakfast Technical Briefing on Biotech Stocks -- Coherus Biosciences, Exelixis, Geron, and Grifols

PR Newswire October 19, 2017

Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS

PR Newswire September 1, 2017

Grifols Phocus Rx® Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces

PR Newswire August 22, 2017

Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol

PR Newswire August 1, 2017

Grifols adds ID RHD XT diagnostic kit to its molecular portfolio

PR Newswire Europe Non Regulatory June 23, 2017

Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples

PR Newswire June 22, 2017

Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma

PR Newswire June 16, 2017

Grifols announces the launch of Erytra Eflexis, the latest advancement in scalable blood typing solutions that easily adapts to different laboratory workflow needs

PR Newswire Europe Non Regulatory June 12, 2017

Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement

PR Newswire June 12, 2017

Grifols Makes Procleix Zika Virus Assay Available for Screening Blood Donations to Countries Accepting CE Mark

PR Newswire Europe Non Regulatory May 23, 2017

Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using Grifols Procleix Panther System in the US

PR Newswire May 9, 2017

Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year Extension of OraSure Technologies Agreement and a New Manufacturing Facility

PR Newswire April 24, 2017

Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program

PR Newswire April 17, 2017

Grifols 2016 Annual Report on Form 20-F filed with the SEC on April 4, 2017

PR Newswire April 4, 2017

Grifols closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million

PR Newswire January 31, 2017

Hologic Completes Divestiture of Blood Screening Business

PR Newswire January 31, 2017

Research Reports Coverage on Biotech Stocks -- Idera Pharma, Ocular Therapeutix, Radius Health, and Grifols

PR Newswire January 27, 2017